These findings provide a new regulatory mechanism for understanding how OA modulates PLD2 activity, highlighting potential therapeutic strategies for SCD1-and PLD2-dependent TNBC and other metastatic cancers. The gene discussed is PLD2; the disease is metastatic malignant neoplasm.